CVS Health Corp. stock (US1266501006): Glenview trims stake after 80% total return and strong Q1 momentum

Hedge fund Glenview Capital has partially taken profits on CVS Health after an 80% two-year total return, following strong first?quarter results and raised guidance that helped drive a sharp share price recovery.

CVS Health Corp. has come back into focus for US investors after hedge fund Glenview Capital disclosed that it rebalanced its position in the pharmacy and health services group following an 80% total return since May 2024, citing progress in a multi?year operational turnaround. The move followed solid first?quarter results and higher full?year guidance from CVS, which contributed to a sharp rebound in the share price, according to PR Newswire as of 05/21/2026 and data summarized by IndexBox as of 05/19/2026.

As of: 05/22/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: CVS Health Corp.
• Sector/industry: Healthcare, pharmacies, health insurance
• Headquarters/country: Woonsocket, United States
• Core markets: United States retail pharmacy, pharmacy benefit management, US health insurance
• Key revenue drivers: Retail pharmacy, pharmacy services, health insurance premiums
• Home exchange/listing venue: New York Stock Exchange (ticker: CVS)
• Trading currency: US dollar (USD)

CVS Health Corp.: core business model

CVS Health Corp. operates a vertically integrated healthcare business built around three main pillars: retail pharmacies, pharmacy benefit management services and health insurance. The company runs a nationwide chain of drugstores in the US and provides prescription fulfillment, over?the?counter medicines and basic health services to consumers.

Through its pharmacy services operations, CVS manages prescription drug benefits for employers, insurers and government programs. This segment negotiates with manufacturers, designs formularies and processes large volumes of claims, making scale a key competitive factor. These services support clients across the US healthcare system and generate fee?based and spread?based revenue streams.

CVS also controls a large health insurance franchise through Aetna, which offers medical, pharmacy and related coverage to commercial, Medicare and Medicaid members. Premiums from these plans form a substantial portion of group revenue, while medical cost management and network contracts influence margins. This integration allows CVS to coordinate pharmacy, insurance and care delivery under one corporate structure.

Main revenue and product drivers for CVS Health Corp.

The company’s top line is primarily driven by prescription drug volumes, health insurance premiums and services provided to corporate and government customers. In its latest reported first quarter, CVS generated revenue of about $100.4 billion and adjusted earnings per share of roughly $2.30, with management highlighting growth across key business units, according to IndexBox as of 05/19/2026.

Retail pharmacy trends remain important, as consumer demand for prescriptions, vaccines and front?store items helps support same?store sales. CVS has been working to improve performance at previously underperforming segments, including parts of its health services operations, which Glenview Capital pointed to as evidence of a cultural and operational turnaround in its statement on the investment, according to PR Newswire as of 05/21/2026.

On the insurance side, membership levels, risk mix and medical cost trends shape profitability. Management recently raised its full?year 2026 guidance after the first?quarter beat, suggesting confidence in earnings power across the integrated platform, according to information compiled by IndexBox as of 05/19/2026. For investors, the balance between growth initiatives and cost control remains a central theme.

Glenview Capital’s position adjustment and shareholder signals

Glenview Capital, a US?based hedge fund, disclosed that CVS has been one of its most concentrated positions over the last two years. The fund reported that shares purchased since May 2024 have generated an 80% total return, underscoring the magnitude of the stock’s recovery over that period, according to PR Newswire as of 05/21/2026.

Following the strong run and improved fundamentals, Glenview rebalanced its CVS position in May 2026, selling 3.75 million shares but keeping the stock among its three largest holdings. The asset manager emphasized continued confidence in CVS’s near?, medium? and long?term prospects while acknowledging the need to manage portfolio concentration, according to the same statement from PR Newswire as of 05/21/2026.

Additional filings show that other institutional investors have also been adjusting their exposure. For example, Banque Cantonale Vaudoise reduced its CVS stake by roughly half during the fourth quarter, according to a regulatory filing summarized by MarketBeat as of 05/22/2026. These moves illustrate how professional investors are reacting to the stock’s rebound and evolving risk?return profile.

Recent share price performance and analyst sentiment

CVS shares have staged a notable recovery in recent months, supported by the earnings beat and raised guidance. Over roughly one month, the stock advanced about 24% as investors reassessed the outlook for the company’s turnaround, according to performance data cited by IndexBox as of 05/19/2026.

More broadly, CVS’s market capitalization recently stood at around $119 billion, reflecting the market’s improved perception of future cash flows, according to a valuation overview by GuruFocus as of 05/21/2026. The site also noted a proprietary GF Score of 80 out of 100 for CVS, a metric it uses to gauge potential for long?term returns.

Equity research coverage remains broadly constructive. MarketBeat reports that 22 analysts currently rate the stock as a Buy and four as a Hold, with an average price target of about $98.68, implying upside versus a recent opening level around $93.35, according to MarketBeat as of 05/22/2026. These targets illustrate how the analyst community is positioning expectations following the latest earnings report.

Why CVS Health Corp. matters for US investors

For US investors, CVS is closely tied to structural trends in the domestic healthcare market. Its New York Stock Exchange listing and large free float make the stock accessible to a wide range of institutional and retail investors in the United States. As a component of major healthcare and broad?market indices, CVS can also influence sector?focused portfolios and ETFs.

The business sits at the crossroads of pharmacy distribution, insurance and healthcare services, giving it exposure to changes in US regulation, drug pricing and consumer behavior. Initiatives around cost management, digital pharmacy and value?based care may shape CVS’s competitive stance in coming years, which is relevant for investors assessing long?term US healthcare themes.

Moreover, the company’s scale and integration can impact bargaining dynamics with drug manufacturers and providers, potentially influencing costs across the system. Developments at CVS therefore tend to attract attention from investors who track policy shifts, reimbursement frameworks and demographic trends such as aging in the US population.

Conclusion

CVS Health Corp. has entered 2026 with renewed momentum, underlined by a solid first?quarter performance, raised guidance and a strong share price rebound that delivered substantial gains for early turnaround investors such as Glenview Capital. The fund’s partial profit?taking, while retaining CVS as a top holding, signals that some professional investors see both achieved success and remaining potential in the evolving strategy.

At the same time, the stock’s recovery and institutional rebalancing show that market perceptions can shift rapidly as earnings, guidance and execution change. For US investors, CVS remains a large, influential healthcare name whose results and strategic decisions are closely tied to broader trends in pharmacy services and health insurance. Monitoring future quarters, regulatory developments and competitive responses will be important in assessing how durable the current improvement in sentiment proves to be.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.